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What Motivations Influence Rheumatoid Arthritis (RA)  
Patients in their Decision to Participate in Clinical Trials? 
AIMS 
 
  This pilot study had several aims: 
 
 - To investigate what motivates rheumatoid arthritis (RA) patients in their decision to enter clinical trials.  
 
 - To determine whether RA patients are motivated by one specific factor, or if RA patients’ motivations were more complex and due to a combination of 
 factors.  
 
 - To compare responses from Clinical Research Facility (CRF) patients with responses from those patients seen for trials in rheumatology departments to 
 determine  if motivations differed between the two patient groups. 
 
METHODOLOGY 
 
  37 patients currently participating in RA clinical trials across two NHS trusts in the North-East of  England were issued with a self-completion  
  questionnaire following informed consent. Questionnaires were identical and included:  
 
 - Basic demographic information. 
 
 - A series of 15 closed ended questions in the form of statements to determine patients’ motivations for entering their clinical trial (Fig.1). 
 
 - One open ended question for any other reasons to be documented. 
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RESULTS 
 
Mean responses for both altruistic statements (“to improve scientific and medical knowledge” and “to help others”), as well as “the potential for improved 
health” and “because I trust the medical staff that treat me” all fell between the values for “agree” and “strongly agree” (Fig. 2).  
The whole group felt that they were not pressurised to participate by research staff. 
Responses between CRF patients and rheumatology department patients showed significant difference (p=0.05) in 4 of the 15 statements. “Best choice of 
treatment”, “more regular follow-ups”, “to get medication not otherwise available on the NHS” and “potential for improved health” were all show to be more 
strongly agreed as motivating factors amongst the CRF group of patients compared to the rheumatology department patients.  
DISCUSSION & CONCLUSION 
 
Clinical research plays an essential role in the development of new and innovative treatments for RA. It is therefore important that we begin to understand the 
needs of the patient in respect to their decision to enter clinical trials. Understanding this will aid recruitment into rheumatology research, as well as allow prac-
titioners to identify the needs of the patients and work with them to make the clinical trial experience a good one. Results from this study are promising, and 
several conclusions can be made: 
 
- Results suggest a combination of influences affect RA patients’ decision to participate in clinical trials. 
 
- The desire for improved health appears to be a major reason for entering RA clinical trials. 
 
- Trust in the clinician and research team appears to be a strong motivation.  
 
- Significant differences in responses between the CRF group and the rheumatology department group would suggest different recruitment strategies for  
 clinical trials should be used in the different clinical areas.  
 
- Further research in a larger sample of the RA population would be beneficial to further clarify these results.  
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Fig.2:  
“I entered a clinical trial as it was my best choice of treatment for my rheumatoid arthritis” 
Fig.1:  
